Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia

doi:10.1016/0091-6749(91)90306-9

Journal of Allergy and Clinical Immunology

Volume 88, Issue 1, July 1991, Pages 96-104

https://doi.org/10.1016/0091-6749(91)90306-9 Get rights and content

Abstract

To determine the best predictors of chronic pulmonary disease in patients with hypogammaglobulinemia, we evaluated the clinical records, chest x-ray films, and pulmonary function tests of 10 patients with X-linked agammaglobulinemia (XLA) followed for a mean of 12.5 years, and 12 patients with common variable immunodeficiency (CVID) followed for a mean of 10.5 years. These patients, most of whom were treated with intramuscular gamma globulin and long-term oral antibiotics, had very few pneumonias after diagnosis. The patients with XLA had 0.10 pneumonias per treatment year, and the patients with CVID had 0.18 pneumonias per treatment year. Seven of the 10 patients with XLA had normal chest x-ray films 8 to 15 years after diagnosis, and none had bronchiectasis. Pulmonary disease was more common and more severe in the group with CVID, but five patients in this group also had normal chest x-ray films after long follow-up. In the entire group of 22 patients, nine of the 10 patients with abnormal chest x-ray films on most recent evaluation already had pulmonary disease at the initial visit (p = 0.00002). These studies indicate that the best predictors of good pulmonary function in patients with hypogammaglobulinemia are early diagnosis and good compliance with gamma globulin replacement therapy and oral antibiotics.

References (19)

PE Hermans et al.
Idiopathic late-onset immunogloublin deficiency
Am J Med
(1976)
ME Conley et al.
Childhood common variable immunodeficiency with autoimmune disease
J Pediatr
(1986)
E Bernatowska et al.
Results of prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment
Clin Immunol Immunopathol
(1987)
ME Conley et al.
Carrier detection in typical and atypical X-linked agammaglobulinemia
J Pediatr
(1988)
ME Conley et al.
A chromosomal breakage syndrome with profound immunodeficiency
Blood
(1986)
B Pirofsky
Intravenous immunoglobulin therapy in hypogammaglobulinemia
Am J Med
(1984)
RU Sorensen et al.
Efficacy and safety of high-dose intravenous immune globulin therapy for antibody deficiency syndromes
Am J Med
(1984)
WB White et al.
Immunoregulatory effects of intravenous immune serum globulin therapy in common variable hypogammaglobulinemia
Am J Med
(1987)
AJ Ammann et al.
Use of intravenous gamma globulin in antibody immunodeficiency: results of a multicenter controlled trial
Clin Immunol Immunopathol
(1982)

There are more references available in the full text version of this article.

Cited by (88)

Predominantly Antibody Deficiencies
2022, Encyclopedia of Infection and Immunity
Predominantly antibody deficiencies (PADs) represent a group of rare disorders characterized by low to extremely reduced immunoglobulin serum levels in the presence or absence of peripheral B cells. Age of onset is variable and depends on the condition, while clinical manifestations of affected patients are heterogeneous and may include invasive infections, recurrent respiratory and gastrointestinal infections, autoimmune manifestations, lymphoproliferation and increased susceptibility to malignant transformation. This article will try to offer an overview of the state of the art on the genetic and clinical features of the most frequent forms of PADs.
Lung disease in patients with common variable immunodeficiency
2020, Allergologia et Immunopathologia
Common Variable Immunodeficiency (CVID) is characterized by an impaired antibody production and a higher susceptibility to encapsulated bacterial infections. Lung disease is considered to be the most important cause of morbidity and mortality.
We analyzed clinical, radiological and functional characteristics in 80 patients with CVID assisted in the Unidad Inmunologia e Histocompatibilidad at Durand Hospital from 1982 to 2018.
Of the 80 patients, 55 showed pathologic lung Computed Tomography (CT). Twenty of them (36.4%) showed bronchiectasis; 26 (47.3%) interstitial involvement associated with nodules and adenopathies called GLILD (granulomatous-lymphocytic interstitial lung disease); and nine patients (16.3%) showed other lesions. Nine percent of patients with lung disease showed CT progression; none of them had spirometry worsening. GLILD patients had normal and restrictive patterns in lung function tests, in equal proportions. Two patients – one with GLILD and the other one with bronchiectasis – had an increase in spirometric pattern severity without CT progression. Lung biopsy was performed in 19% of GLILD patients, all of whom had histopathologic diagnosis of Lymphoid Interstitial Pneumonia (LIP).
GLILD is the major cause of lung disease in CVID. Computed tomography is useful for diagnosis but not necessary in follow-up, in which functional tests should have better correlation with clinical evolution, reducing radiation exposure. Biopsy should be indicated when the clinical diagnosis is unclear. Treatment should be considered whenever there is clear evidence of disease progression.
Chronic Lung Disease in Primary Antibody Deficiency: Diagnosis and Management
2020, Immunology and Allergy Clinics of North America
Citation Excerpt :
Frequent and/or severe respiratory infections can cause structural lung damage that may promote chronic pulmonary disease.8 Moreover, delay in PAD diagnosis is associated with fixed pulmonary obstruction, chronic atelectasis, pulmonary fibrosis, and bronchiectasis.6,9,10 Earlier recognition of PAD potentially can lead to interventions that reduce the frequency of respiratory infections, hospital admissions, and improve survival.11–13
X-Linked Agammaglobulinaemia: Outcomes in the modern era
2017, Clinical Immunology
Colonel Ogden Bruton reported X-Linked Agammaglobulinaemia in 1952 and treated the child with replacement immunoglobulin therapy. Over 60 years later, the treatment for XLA has largely remained unchanged. Replacement immunoglobulin lacks the isotypes IgA and IgM, leading to concerns that patients continue to experience recurrent sinopulmonary tract infections and be at increased risk of bronchiectasis. There is potential hope of earlier diagnosis with newborn screening, and a potential cure for these patients, in the form of gene therapy. However, it is first necessary to evaluate current management and outcomes to aid decisions regarding further research and clinical trials. This article reviews current management and outcomes of XLA, whilst identifying gaps in our knowledge base that may need answering before we proceed with novel diagnostic methods and treatment for XLA.
Lung Disease in Primary Antibody Deficiencies
2016, Journal of Allergy and Clinical Immunology: In Practice
Primary antibody deficiencies (PADs) are the most common form of primary immunodeficiency and predispose to severe and recurrent pulmonary infections, which can result in chronic lung disease including bronchiectasis. Chronic lung disease is among the most common complications of PAD and a significant source of morbidity and mortality for these patients. However, the development of lung disease in PAD may not be solely the result of recurrent bacterial infection or a consequence of bronchiectasis. Recent characterization of monogenic immune dysregulation disorders and more extensive study of common variable immunodeficiency have demonstrated that interstitial lung disease (ILD) in PAD can result from generalized immune dysregulation and frequently occurs in the absence of pneumonia history or bronchiectasis. This distinction between bronchiectasis and ILD has important consequences in the evaluation and management of lung disease in PAD. For example, treatment of ILD in PAD typically uses immunomodulatory approaches in addition to immunoglobulin replacement and antibiotic prophylaxis, which are the stalwarts of bronchiectasis management in these patients. Although all antibody-deficient patients are at risk of developing bronchiectasis, ILD occurs in some forms of PAD much more commonly than in others, suggesting that distinct but poorly understood immunological factors underlie the development of this complication. Importantly, ILD can have earlier onset and may worsen survival more than bronchiectasis. Further efforts to understand the pathogenesis of lung disease in PAD will provide vital information for the most effective methods of diagnosis, surveillance, and treatment of these patients.
Respiratory manifestations and management in children with Common Variable Immunodeficiency
2016, Paediatric Respiratory Reviews
Common variable immunodeficiency is an antibody deficiency that usually presents in childhood with recurrent sino-pulmonary infections. Diagnostic delay is frequent and thus respiratory morbidity is common, ranging from recurrent suppurative bronchitis to bronchiectasis. Immunoglobulin replacement therapy is the mainstay of treatment, whilst prophylactic antibiotic therapy and muco-ciliary clearance are additional treatment options. This review examines the diagnosis and management of respiratory issues in children with CVID.

View all citing articles on Scopus

^☆: Supported in part by The Immune Deficiency Foundation and by National Institutes of Health Grant AI 25129.

View full text

Original articleRetrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia☆

Abstract

Am J Med

J Pediatr

Clin Immunol Immunopathol

J Pediatr

Blood

Am J Med

Am J Med

Am J Med

Clin Immunol Immunopathol

Original article
Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia☆